Acute disseminated encephalomyelitis medical therapy: Difference between revisions
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The analogy between the [[pathogenesis]] of [[ADEM]] and [[MS]] forms the basis of the use of [[high-dose]] [[steroids]], [[plasma exchange]] and [[intravenous]] [[immunoglobulin]] for the [[treatment]] of [[ADEM]]. | |||
==Medical Therapy== | ==Medical Therapy== | ||
Revision as of 07:06, 21 November 2022
|
Acute disseminated encephalomyelitis Microchapters |
|
Differentiating Acute disseminated encephalomyelitis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute disseminated encephalomyelitis medical therapy On the Web |
|
American Roentgen Ray Society Images of Acute disseminated encephalomyelitis medical therapy |
|
Acute disseminated encephalomyelitis medical therapy in the news |
|
Blogs on Acute disseminated encephalomyelitis medical therapy |
|
Directions to Hospitals Treating Acute disseminated encephalomyelitis |
|
Risk calculators and risk factors for Acute disseminated encephalomyelitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sujaya Chattopadhyay, M.D.[2]
Overview
The analogy between the pathogenesis of ADEM and MS forms the basis of the use of high-dose steroids, plasma exchange and intravenous immunoglobulin for the treatment of ADEM.